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ABSTRACT
Background: Warts are widespread cutaneous and mucosal infections caused by
human papilloma virus. Resistance to treatment is the main concern while
dealing with cutaneous warts. Previous research has defined an ideal wart
therapeutic modality as the one that is able to clear all present warts painlessly
with no recurrences. Current therapeutics are still far away from meeting this
definition. The growing evidence of the role of cell mediated immunity in wart
resolution supports the use of various immunotherapeutics in treating cutaneous
warts especially the recalcitrant ones. Candida antigen injection has recently
emerged as a potential effective therapeutic option that needs confirmatory
research trials on a large scale. The aim of this work is to evaluate the efficacy of
intralesional Candida antigen injection in treating resistant warts in patients
attending our clinic over a period of one year.
Subjects &Methods: Ninety-two adult patients with recalcitrant warts were
included in this study. All patients were subjected to adequate dermatologic
examination of warts regarding site, type and number, presence of distant warts
at baseline and at each follow-up visit. All patients included were injected with
0.3ml of 1/1000 Candida antigen solution into the largest wart for 5 sessions
biweekly.
Results: out of the 92 patients,80 patients (92.3%) responded to therapy; 55
patients (59.7%) achieved complete resolution, 25 (27.1%) patients demonstrated
partial response and 12patients (13%) showed no response.
Conclusion: Our results indicate Candida antigen is an efficacious treatment
option of recalcitrant warts that can be adopted in clinical practice.
Keywords: Wart, Resistance, Candida

INTRODUCTION
arts or verrucae are the known medical
terms used to describe cutaneous and
mucosal infections caused by Human Papilloma
Virus (HPV). Addressing cutaneous warts as an
old and seemingly everlasting clinical problem
is mandatory due to several causes. First is the
high incidence of cutaneous warts both in
Egypt and worldwide. The lack of a specific
antiviral therapy together with the varied
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untrusted efficiencies of current treatment
options add more to the severity of the problem
[1].

Although the great majority of warts are
claimed to resolve spontaneously within no
more than 2 years, about one third of cases
persist despite treatment. There's no exact
definition for resistance. However, it's been
accepted to be defined as failure to respond to
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five subsequent treatments over a period of 6
months [2].
Previous research has defined an ideal wart
therapeutic modality as the one that is able to
clear all present warts painlessly with no
recurrences and with no scarring. Current
therapeutic options are still far away from
meeting this definition. Standard therapeutic
modalities for warts, especially resistant ones,
are usually destructive [3].
Destructive options include surgical procedures
such as electrocautery, laser ablation, surgical
excision and aggressive cryotherapy. They also
include medical options such as high
concentration trichloroactetic acid, Salicylic
acid and anti-proliferative agents such as
podophyllotoxin, 5-fluorouracil and bleomycin
[4].

Most of these options require multiple sessions
with high incidence of adverse effects as
scarring and recurrence. The major drawback
for those traditional treatments is that they are
limited to local application and can’t act
systemically. Thus, they are not convenient for
patients with distant and multiple warts. Hence,
the need for an effective systemic therapeutic
modality [5].
The growing evidence of the role of cell
mediated immunity in wart resolution has
supported
the
use
of
various
immunomodulatory options in the treatment of
cutaneous warts especially in patients with
multiple and recalcitrant warts. Those include
topical sensitizers e.g. diphenylcyprone,
proinflammatory cytokines e.g. interferons, oral
levimasol and intralesional antigen therapies
e.g. BCG vaccine and Candida antigen therapy
[6].

Back in 1990, Cenci et al. demonstrated on
mice that Candida antigen treatment produced
high levels of IFN-γ in vitro. Recently in 2017,
Nofal et al., illustrated a significant correlation
between the response of common warts to
Candida antigen treatment and the levels of
IFN-γ. Both studies support the mounting
evidence on the effect of Candida antigen
treatment through stimulating cell medicated
immunity particularly a TH1 response [5].
Nassar A., et al
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PATIENTS &METHODS
Ethical considerations
The protocols and informed consent forms used
in this study were approved by the Institutional
Review Board (IRB) of Zagazig University. All
participants signed a written informed consent
and filled a written survey including
demographic and clinical data. The work
described has been carried out in accordance
with The Code of Ethics of the World Medical
Association (Declaration of Helsinki) for
experiments involving humans.
Sampling:
Ninety-two cases complaining of persistent
warts, resisting at least one modality, were
recruited from attending cases in the period
from January 2017 to October 2017. Wart
persistence was defined as persistence of warts
despite being treated for more than one year.
Study design:
All patients were subjected to:
Thorough history taking and a detailed
questionnaire including obtaining their sociodemographic data (Age, Sex, Residence… etc),
duration of wart presence, its course and
previous therapies used.
Adequate clinical dermatologic examination of
warts regarding site, type and number, presence
of distant warts at baseline and at each followup visit. Patients were advised not to use any
other wart-directed therapy during the study
period.
Candida antigen injection:
all patients
included were injected, without prior
sensitization, with 0.3ml of 1/1000 Candida
antigen solution (Candida albicans 1:20 w/v
10ml vial, Allergy laboratories, INC, Oklahoma
City, USA) into the largest wart, if multiple,
using an insulin syringe. Injections were done
biweekly for a total of 5 subsequent noninterrupted injections. Photographic evaluation
and comparison from baseline photographs
were done at each visit. Immediate and late
adverse effects were recorded at each visit. All
patients were followed for up to 6 months after
completion of therapy to detect any recurrence.
Statistical Analysis:
The collected data were analyzed by computer
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using Statistical Package of Social Services
version 24 (SPSS), Data were represented in
tables and graphs, Continuous Quantitative
variables e.g. age were expressed as the mean ±
SD & median (range), and categorical
qualitative variables were expressed as absolute
frequencies (number) & relative frequencies
(percentage).
Suitable statistical tests of significance were
used after checked for normality. The results
were considered statistically significant when
the significant probability was less than 0.05 (P
< 0.05). P-value < 0.001 was considered highly
statistically significant (HS), and P-value ≥ 0.05
was considered statistically insignificant (NS).
RESULTS
Demographic characteristics of patients under
study:
Our study included Ninety-Two (92) adult
patients; Forty-Two (42) males and Fifty (50)
females). Their ages ranged from Twenty to
Forty-seven (47) years old with a mean of
33.37 ± 6.96.
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Type &Duration of warts in patients under
study
Table 1 shows that 39.2% of the patients under
study suffered from warts for less than 2 years,
while 60.8% of them had warts for 2 years or
more. Results also show 26.1% had common
warts only, 58.7% had only planter warts and
that 15.2% of patients had both planter and
common warts.
Results by Response
Table 2 demonstrates that out of the 92
patients,80 patients (92.3%) responded to
therapy; 55 patients (59.8%) achieved complete
resolution, 25 (27.2%) patients demonstrated
partial response and 12patients (13%) showed
no response.
Figure 1 demonstrates Multiple recalcitrant
planter warts in a 21 year old female showing
complete response after only 3 biweekly
injection sessions. No recurrence upon followup.

Table 1: Type &Duration of wart among studied patients
Duration of warts
Duration of warts
< 2 years
≥ 2 years
Wart Type
Common warts
Planter warts
Both

Studied patients (N=92)
No.
(%)
36
56

39.2
60.8

24
54
14

26.1
58.7
15.2

Table 2: Response to Candida antigen immunotherapy among studied patients.
Response to Candida antigen
Studied patients (N=92)
No.
(%)
Non responder
12
13
Partially responder
25
27.2
Responder
55
59.8
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Figure (1): Complete response of planter warts to Candida treatment.

DISCUSSION
Warts represent one of the commonest
troublesome dermatological problems for both
dermatologists and patients. Even though most
warts regress spontaneously within two years,
many warts fail to resolve even with using more
than one therapeutic modality. The recalcitrant
nature and the frustrating recurrence pose a
difficult therapeutic dilemma as no particular
therapy has demonstrated a complete efficacy
[7].

The growing evidence of the role of cell
mediated immunity in wart resolution has
supported
the
use
of
various
immunomodulatory options in the treatment of
cutaneous warts, especially in patients with
Nassar A., et al
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multiple and recalcitrant wart, the most
common of which is Candida antigen
intralesional injection that has proven effective
in treating warts since 1999 [2].
In the present study, Candida antigen was used
to treat recalcitrant warts of different types and
durations in adult patients. Overall, 59.8% of
our patients were complete responders, 27.2%
demonstrated partial response and 13% didn’t
show adequate response to the therapy
employed. In general, our results are
comparable to those of other studies. However,
the efficacy is somewhat lower than many
others.
Our results are can be said to be comparable to
[8]
where they applied Candida antigen injection
421 | P a g e
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on eighty-seven adult and pediatric patients
with recalcitrant warts and complete response
was seen in 51% of patients, partial response in
41% and no response in 8%. Majid et al. used
0.1ml of intralesional Candida for a total of 3
weeks at a 3 week interval sessions in adults
with recalcitrant warts and could achieve a
complete response in 55.9% of included
patients [9].
Nofal et al., in 2017 could achieve a complete
response in 61.1% of patients under Candida
treatment for five biweekly sessions [5]. Higher
response rates could be seen with [10] where
72% of patients were complete responders. In
2001, Johnson et al. could, by using only 3
intralesional Candida injections, achieve
complete response in 70% of patients [11].
CONCLUSION
Our
data
indicate
that
intralesional Candida antigen
therapy
for
cutaneous warts is an efficacious option in a
clinical practice setting. Our results add to the
literature a large Egyptian retrospective series
reported to date and treatment outcomes are
similar to previously reported studies
evaluating this therapeutic modality. Candida
antigen injection should be considered in all
patients with cutaneous warts, particularly those
with multiple recalcitrant warts. Advantages
include affecting distal warts, easy use and lack
of scarring and systemic adverse effects.
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